Enanta Pharmaceuticals | ENTA - Créances Commerciales





Créances Commerciales Changement Date
AbbVie USD 12.48B 110M 2026-03
Amgen USD 10.23B 1.09B 2026-06
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 8.56M 7.13M 2026-06
AstraZeneca USD 18.86B 972M 2026-06
BioCryst Pharmaceuticals USD 110.76M 3.94M 2026-06
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 5.06B 314M 2026-06
GlaxoSmithKline GBP 8.07B 137M 2026-06
Halozyme Therapeutics USD 453.33M 4.66M 2026-06
Heron Therapeutics USD 89.59M 8.54M 2025-12
Immunic USD 333K 156K 2025-12
Incyte USD 1.13B 73.7M 2026-06
Insmed USD 215.32M 36.77M 2026-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
J&J USD 22.54B 1.21B 2026-03
Karyopharm Therapeutics USD 23.36M 2.82M 2026-03
Ligand Pharmaceuticals USD 54.8M 6.25M 2026-03
Merck USD 12.21B 435M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Novartis USD 9.85B 252M 2026-06
Novavax USD 106.45M 72.27M 2025-12
Pfizer USD 16.19B 19M 2026-06
PTC Therapeutics USD 219.92M 38.3M 2026-03
Roche Holding CHF 13.34B 1.44B 2026-06
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
Vertex Pharmaceuticals USD 2.13B 138.2M 2026-06